Molecular study of the presence and transcriptional activity of HPV in semen

The study was approved by our University Hospital’s Institutional Review Board (Ethical Committee of “Sapienza” University of Rome—Azienda Ospedaliera Policlinico Umberto I, Ref 6564, Prot. 0044/2022) and all patients gave their informed written consent.

We enrolled consecutive Caucasian men between January 2022 and June 2022, which were sexually active and over 18 years of age, attending the Laboratory of Seminology—Sperm Bank “Loredana Gandini”, Department of Experimental Medicine at “Sapienza” University of Rome, for andrological evaluation, and the Infectious Disease Department of the Policlinico Umberto I Hospital—“Sapienza” University of Rome, for STIs assessment.

For each subject, the following clinical and anamnestic data were collected by a detailed questionnaire during the andrological and STIs evaluation: previous andrological and non-andrological pathologies, anthropometric data (height, weight, Body Mass Index “BMI”), lifestyle (such as current smoking and alcohol drinking), sexual behaviors (stable sexual inter-courses with the same partner or promiscuous sexual intercourses with a number of partners > 1), previous and/or current urogenital tract infections, anti-HPV vaccination, any previous and/or current HPV infection of the patient and sexual partner. In particular, we referred to a personal history of anogenital HPV infection as an anogenital infection of the patients enrolled caused by HPV, diagnosed following epithelial scraping of external genitalia, either currently present or previously treated. We also investigated the history of anogenital HPV infection of their sexual partners considering patients with a partner with an HPV infection diagnosed within 12 months.

Men taking any medications (antibiotics, anabolic hormones) and/or with medical conditions associated with impaired semen parameters (endocrine diseases, testicular trauma, clinically relevant varicocele, cryptorchidism, testicular or other cancer, previous chemotherapy and/or radiotherapy, Klinefelter syndrome and other chromosome abnormalities or genetic syndromes) were excluded from the study.

Based on clinical data and on medical history, the enrolled subjects were divided into two study groups: Group A, which includes patients with risk factors for HPV infection (unprotected sexual intercourses with multiple partners, partners with HPV infection diagnosed within 12 months, personal history of anogenital HPV infection and/or genital warts), and Group B, which comprises subjects with no known risk factors for HPV infection (Table S1).

Semen samples were collected by masturbation after 3–5 days of abstinence. All samples were allowed to liquefy at 37 °C for 60 min and were then assessed according to World Health Organization “WHO” 2010 [21]. The following variables were taken into consideration: ejaculate volume (ml), sperm concentration (10⁶ per ml), total sperm number (10⁶ per ejaculate), progressive motility (%) and morphology (% abnormal forms).

To assess the possible presence of ASAs, in each semen sample we performed direct SpermMar Test (FertiPro N.V., Beernem, Belgium), evaluating the percentage of motile sperm that presented latex particles (coated with human IgG or IgA) bound and the site of the bond (head, midpiece, tail). Positivity was defined as the SpermMar Test showing binding > 20%, but clinical relevance was considered with a binding  percentage  > 50% [22].

To evaluate the feasibility of HPV-DNA detection in seminal fluid with nested PCR, a semen sample with WHO parameters within 25th percentile collected by a patient with a negative history of HPV-DNA detection and physical examination for HPV infection (negative control) was spiked with an inactivated HPV-16 pellet (Helix Elite™ Molecular Standards).

In particular, the lyophilized pellet, containing 100.000 copies of inactivated HPV-16, was rehydrated with 200 µl of sterile nuclease-free water, following the manufacturer’s instructions.

The negative control sample was divided into 10 aliquots of 200 µl and the first one was spiked with the rehydrated pellet (200 µl), proceeding with serial dilutions 1:2 to achieve seminal aliquots containing 50.000, 25.000, 12.500, 6.250, 3.125, 1.562, 781, 391, 195 and 98 HPV copies, respectively.

All aliquots were processed for total DNA extraction and HPV-DNA detection, performing the same molecular techniques used for semen samples of the recruited subjects.

DNA extraction from aliquots of total semen samples (200 µl) was performed by QIAamp DNA mini kit (Qiagen, Milan, Italy), according to the manufacturer’s instructions. Extracted DNA was quantified by NanoDrop ND-2000 (Thermo Fisher Scientific, Waltham, MA, USA) and underwent molecular analysis to detect HPV-DNA.

For each sample, the presence of amplifiable DNA was tested by qualitative PCR using HLA1/HLA2 primers, which are specific for a highly conserved region of a human gene belonging to the family coding for the HLA complex. The presence of HPV was then investigated by nested PCR using MY09/MY11 as outer primers [23] and GP5 + /GP6 + as inner primers [24], which are specific for the viral gene coding capsid protein L1 (Table S2).

The amplification reaction with HLA1/HLA2 and MY09/MY11 primers was carried out using 100 ng of DNA in 25 μl under the following PCR conditions: 95 °C for 2 min followed by 35 cycles at 95 °C for 45 s, 54 °C for 1 min, 72 °C for 1 min and a final extension step at 72 °C for 7 min. The nested PCR with GP5 + /GP6 + primers was carried out in 25 μl using 1 μl of the first-round product under the following PCR conditions: 94 °C for 2 min followed by 30 cycles at 94 °C for 30 s, 45 °C for 30 s, 72 °C for 20 s and a final extension step at 72 °C for 5 min [25]. In each amplification reaction, DNA from a semen sample of a patient with negative history and physical examination for HPV infection was used as negative control, while the same DNA spiked with an inactivated HPV-16 pellet was used as positive control.

A 5 μl of each PCR product was then used for electrophoresis on 1.5% agarose gel to check the presence and exact length of the amplified fragments (230 bp, 450 bp and 150 bp for PCR products obtained with HLA1/HLA2, MY09/MY11 and GP5 + /GP6 + primers, respectively).

HPV-positive samples underwent genotyping in Real Time PCR using “HPV HR/LR 23 Types Detection Kit RQ” (Experteam, Italy), which identifies the 23 most common HPV types, of which 14 HR-HPVs (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) e 9 LR-HPVs (6, 11, 26, 53, 67, 70, 73, 81, 82). The amplification was carried out in a 48-well plate with Step One Real Time PCR System (Applied Biosystems, Carlsbad, CA, USA), according to the manufacturer's instructions.

CT values below 37 suggested positivity to one or more viral genotypes (multiple infection).

To quantitatively detect HPV transcriptional activity in semen, we analyzed E6 and E7 expression using specific probes for the most frequent strains (HPV6, 16, 18, 31, 53, 58).

Total RNA was isolated from an aliquot of 500 µl of semen using guanidine isothiocyanate lysis buffer (Trizol, Gibco BRL, NY, USA) with a step of digestion with deoxyribonuclease I (DNase I, RNase-free, ZYMO Research, Irvine, CA, USA), according to the manufacturer’s instructions.

Reverse transcription (RT) for cDNA synthesis was carried out on 200 ng of RNA extracted from each sample in a final reaction volume of 50 μl, using the High Capacity cDNA RT kit (Invitrogen Corporation, San Diego, CA, USA), according to the manufacturer’s instructions. Quantification of mRNA was carried out using real-time 5′exonuclease RT-PCR fluorogenic assay (TaqMan PCR, Applied Biosystems) using the Light Cycler 480 II sequence detector (Roche, Monza, Italy). Specific primer pairs, at a final 600 nM concentration, and the proper probe double-labelled (6-carboxy-fluorescein [FAM] and 6-carboxy-tetramethyl-rhodamine [TAMRA], at 5′ and 3′ ends, respectively), at a final 300 nM concentration, were added to Light Cycler Probe Master Mix (Roche) in a 20 μl volume. TaqMan probes and primers (shown in Table S3) were designed to anneal in the HPV E6/E7 gene, as previously described [26]. RT-PCR conditions for amplifying target genes and GAPDH were as follows: pre-incubation 10 min at 95 °C; amplification for 45 cycles (95 °C for 10 s, 60 °C for 30 s, and 72 °C for 1 s); cooling 40 °C for 30 min. Copy numbers were calculated by means of an external standard curve generated by amplifying serial tenfold dilutions (10–10⁸ copies) of a DNA plasmid containing the E6/E7 fragment of each genotype. These type-specific standards were generated by cloning E6/E7 fragments in Topo TA vector (Invitrogen, San Diego, California, USA) [25]. The lower limit of sensitivity of the assay is about 10 copies/ng of total DNA. All samples were tested in triplicate along with positive (DNA templates purified from HPV-positive samples) and negative (cDNA from HPV-negative samples and no cDNA) controls. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and β-glucuronidase (GUS) were used as endogenous genes for sample normalization, while protamin 1 (PRM1) mRNA, a sperm-specific transcript, was used as control for sperm RNA extraction, using RT-PCR (TaqMan™ Gene Expression Assay, Applied Biosystems) [27].

Continuous variables have been expressed as a mean ± standard deviations or medians and interquartile range, where appropriate, in relation to the normality of the value distributions evaluated with the Kolmogorov–Smirnov test. Comparisons among the two groups (A and B) have been carried out using student’s t (independent t test) or Mann–Whitney U tests for independent samples, where appropriate. Categorical variables, expressed as percentages, are evaluated with the χ² test. Correlations were computed using Spearman’s correlation test.

We enrolled 185 sexually active subjects aged ≥ 18 years (36.0 ± 8.3 years, range 18–60 years). 85/185 had risk factors for HPV infection (Group A); conversely, 100/185 reported no known risk factors for viral infection (Group B). Age and BMI significantly differed between the two groups (age: 34.2 ± 9.7 vs. 37.6 ± 6.6 years, Group A vs. B respectively, p = 0.002; BMI: 23.8 ± 3.0 vs. 25.4 ± 3.1 kg/m², respectively, p < 0.001).

Table 1 shows relevant demographics and medical history from the two groups. As expected, Group A had a higher incidence of genito-urinary infections (Mycoplasma spp., Chlamydia spp., Klebsiella spp., Citrobacter spp., Escherichia coli, Staphylococcus aureus, Proteus spp., Candida spp.) and other viral coinfections (HSV, HIV, HBV, HCV). On the other hand, unprotected sexual intercourses and anti-HPV vaccination rates were unsatisfactorily low in both groups (Table 1).

We detected seven azoospermic and one cryptozoospermic subject in the overall caseload; in particular, in Group A there were three azoospermic and the cryptozoospermic subject, while 4 azoospermic subjects were in Group B. These subjects were excluded from the statistical analyses of semen parameters. Table S4 describes semen parameters in the two groups.

The use of the molecular standard allowed us to confirm the efficiency of the DNA extraction technique and nested PCR in identifying HPV-DNA in semen sample.

We proved that nested PCR was able to reveal HPV-DNA up to a detection limit of approximately 195 copies, as shown in Fig. 1. Below this threshold it is plausible to hypothesize that the viral genome cannot be detected in semen using nested PCR as investigation technique.

In the whole caseload molecular analysis revealed seminal HPV prevalence in 16/185 subjects (8.6%). Based on medical history, 10/16 (62.5%) subjects with HPV in semen had specific risk factors for HPV, while 6/16 (37.5%) reported no known risk factors for viral infection (Fig. 2a). In particular, we observed seminal HPV presence in 10/85 (11.8%) patients of Group A and in 6/100 (6%) men of Group B (p = 0.195) (Fig. 2b). Moreover, when considering the total of subjects with at least one partner of the couple with a HPV history (45/85 subjects), the prevalence is 11.1% (5/45 subjects), in subjects with multiple sexual partners is 11.6% (5/43 subjects), while it increases up to 27.3% when considering the subgroup of subjects with genital warts (6/22 subjects) and to 30.6% (26/85 subjects) in men with previous and/or current anogenital HPV infection (Fig. S1).

Among patients with HPV-positive semen, we observed one azoospermic and one cryptozoospermic subjects (both belonging to Group A). Table 2 shows the comparison of semen parameters between HPV positive and negative patients. No significant difference in sperm parameters was found, although this may be due to the limited number of positive patients observed. Likewise, the immunological study revealed no positivity in any patient with HPV-DNA in semen.

Finally, we detected that the only variables significantly associated with the risk of HPV positivity in seminal fluid were the presence of genital warts (OR 5.79, 95% CI 1.84–18.23, p = 0.003) and previous anogenital HPV infection (OR 4.93, 95% CI 1.62–14.98, p = 0.005). The other relevant clinical risk factor investigated, multiple sexual partners, was found not to be significantly associated with HPV-DNA presence in semen (OR 1.51, 95% CI 0.50–4.62, p = 0.466). Regarding semen cytological parameters, none was found to be significantly associated with the presence of HPV in semen.

Genotyping of HPV-positive semen samples allowed to detect both LR-HPVs and HR-HPVs, as shown in Table 3. Only for one patient tested positive for the qualitative research of viral DNA by nested PCR it was not possible to identify the specific genotype, suggesting the presence of a strain not detectable by the kit used in our study. Similarly, it should be stressed that for each sample it is not possible to exclude positivity to other non-investigated genotypes. In samples in whom genotyping was successful, 9/15 men (60%) showed a multiple infection and 13/15 (86.7%) showed positivity to HR-HPVs.

To ascertain whether HPV-DNA positivity were also associated to HPV genome transcriptional activity, the presence of mRNA copies of the more common low-risk (HPV6, 11) and high-risk (16, 18, 31, 33, 53, 58) genotypes was tested with sensitive Real Time PCR assays (RT-PCR), after DNA removal. However, based on the biological material available and the genotype-specific HPV probes used, 6 out of 16 samples with HPV-DNA in semen could be analyzed for E6 and E7 HPV-RNA expression (Table S5).

While detecting the expression of the endogenous genes (GAPDH and GUS) and confirming an efficient sperm RNA extraction (PRM1 CT mean = 29.01), RT-PCR did not detect HPV-E6 and E7 expression in any HPV-DNA positive semen sample tested (Fig. 3), suggesting the absence of potentially infectious virions in this biological fluid.

The immunological study performed in our caseload highlighted the positivity to ASAs only in three semen samples, two of which belonging to Group A and one to Group B. The ASAs binding percentages were the following:

These samples were negative for HPV presence in semen investigated by nested PCR.

HPVs are the etiological agents of one of the most common sexually transmitted diseases causing a variety of clinical manifestations ranging from warts to cancer.

In human semen HPV shows a variable prevalence from 1.3% to 72.9% with a peak of 65.4% in reproductive age [28]. Unlike women in whom the prevalence is high after the onset of sexual activity and then shows a decrease, in men the prevalence of infection remains high even in older age [29].

In the male genital tract, HPV can be localized in different anatomic sites, such as penis shaft, glans, coronal sulcus, prepuce, scrotum, anal and perianal canal but also urethra and semen [30]. Depending on the anatomic site, HPV prevalence and load display a significant variability showing higher proportions in samples obtained by epithelial scraping of external genitalia than in semen [31, 32]. In the latter site, the literature shows an extremely variable prevalence of HPV, ranging between 7.8% [33] and 53.8% [13].

To date, HPV detection in semen is not much applied in clinical practice and no protocol is recognized as gold standard for its detection in this biological fluid. Literature shows different methodologies to detect HPV in semen, such as PCR, Real Time PCR and hybridization assays. As each of these techniques exhibits a different ability to detect the virus based on the specific molecular principle, HPV detectability in semen might change. This could explain at least in part the wide range of seminal HPV prevalence reported in literature (Table 4). However, it should be stressed that all the above-mentioned methods are valid to detect HPV-DNA but using the same technique the prevalence may differ, suggesting the contribution of several factors that are often not easily identifiable. Unfortunately, to date there are no studies aimed at comparing the ability of the various techniques to detect HPV in semen. Thus, the identification of a gold standard protocol is lacking in literature. In 2009 Coutlee et al. compared several methods for detection and typing of HPV in biological fluids, although semen was not included [34]. Describing benefits and limitations of the various molecular procedures, this study showed that nucleic acid amplification techniques are ideal methods to detect infection with low viral burden. Conversely, other molecular strategies, such as in situ hybridization assays, could cause false negative results in presence of lower amounts of HPV-DNA.

For this reason, one of the main purposes of our study was to evaluate the effective ability of a common molecular biology technique, the nested PCR, to identify HPV genome in seminal samples. Contamination of a negative control with an inactivated HPV-16 pellet allowed us to monitor the efficiency of the molecular methods used in our study, confirming the ability of the nested PCR to reveal HPV-DNA in semen up to a detection limit of approximately 195 copies. Below this threshold it is reasonable to hypothesize that this technique could lead to false negatives in samples with a reduced viral load.

In our study, the data about seminal HPV prevalence from the two groups resulted lower than that shown by most papers in previous literature [7‐13, 16, 32, 35‐48] (Table 4). The low prevalence we found would not seem to be due to vaccination, which resulted inadequate in the overall caseload (10.3%, 19/185 patients). This discrepancy may derive from multiple factors, including geographical area from which the recruited subjects come, molecular methods chosen to reveal the viral genome, numerosity of the caseload and criteria by which the patients were selected. In particular, literature data show a HPV prevalence ranging from 4.88 to 46% in semen of infertile patients [7, 8, 10, 11, 13, 16, 32, 33, 35, 37‐43, 45], and from 10 to 71% in semen of men with risk factors for viral infection [9, 12, 13, 44‐46]. The prevalence we observed in semen samples of Group A (11.8%) is within the lower range shown by the literature for subjects with risk factors for HPV infection.

As expected, considering the total number of HPV-DNA positive samples detected in our study, the Group A displayed a higher HPV prevalence in semen compared to the Group B (62.5% vs. 37.5%, respectively). It should be stressed that the positivity to HPV in semen of patients with neither risk factors nor visible genital lesions suggests the presence of an unrecognized infection with a potential negative impact on reproductive health.

In Group A, 10.6% and 12.9% of patients were affected by urogenital and viral coinfections, respectively (compared to none in Group B), which further increase the probability of HPV infection. This observation agreed with the study of La Vignera et al. (2015), who demonstrated that patients with male accessory gland infections showed a significantly higher frequency of HPV infection compared with fertile controls [49].

Our results highlighted that the presence of HPV-DNA in semen was strongly associated with certain risk factors, such as sexual intercourse with multiple partners, the presence of genital warts and a history of previous HPV infection. Specifically, the risk of detecting the viral genome in semen was increased by approximately sixfold in the presence of genital warts and fivefold in the presence of previous infection.

To our knowledge, this is one of the few studies currently in the literature aiming to evaluate any association between HPV in semen and the presence of risk factors. In particular, the relatively high prevalence of HPV in the semen of men with genital warts (27.3%) and previous and/or current anogenital infection (30.6%) suggests the importance of HPV semen screening in this category of patients. In agreement with our data, also Foresta et al. reported a high HPV prevalence in semen of men with genital warts and men with HPV-positive female partners (53.8% vs. 40.9%, respectively) [13]. Subsequently, analyzing HPV prevalence in semen of 213 healthy male volunteers of which 15% with flat penile lesions and 2% with condyloma acuminata, Luttmer et al. proved that HPV-DNA in semen was associated with HPV infections of the penile epithelium. Moreover, as well as in our caseload, not all clinically detected flat penile lesions were correlated with HPV detection in semen [46]. Afterwards Cortés-Gutiérrez et al. found a HPV prevalence of 71% in semen of fertile men displaying genital warts [45]. Finally, in 2019 Capra et al. investigated HPV-DNA in semen of 22 men with female HPV-positive partner affected by high-grade squamous intraepithelial lesions (HSIL), finding seminal presence of HPV in 45% of cases. Interestingly, none of the infected males showed visible lesions [25]. As observed by Capra et al., also in our study not all HPV-positive patients exhibited visible genital lesions typical of viral infection.

The impact of seminal HPV presence on sperm parameters is a controversial topic. Most studies have observed a reduction of semen quality in HPV-positive men and the parameter most impaired seems to be sperm motility [7, 8, 10‐12, 16, 35, 38, 39, 42], the reduction of which is intrinsic in the infertile nature of the subjects studied.

Some authors have also revealed the presence of ASAs, suggesting that HPV in semen may represent an antigenic stimulation that would contribute to further reduce male fertility [15, 16]. However, other studies have found no significant association between seminal HPV presence and low semen quality [32, 33, 37, 43], not even in relation to sperm chromatin integrity [43, 45, 47]. Recently, Cannarella et al. found no significant difference in sperm concentration, total sperm count, progressive motility, morphology and leukocyte concentration between LR-HPV positive patients and controls with no evidence of HPV-DNA in semen, despite the prevalence of oligozoospermia and leukocytospermia were significantly higher in LR-HPV positive men [40]. Moreover, in another recent study, HPV in semen did not appear to correlate with any sperm parameters, excluding progressive motility and morphology; HPV positivity did not even modify DFI rates, except when comparing HR and LR genotypes, suggesting that HR-HPVs could specifically affect sperm DNA integrity [44].

In agreement with these latest studies, we found that the presence of HPV in semen was not correlated with impaired semen quality. However, it should be stressed that the lack of correlation may be due to the small number of positive patients found (16/185). Moreover, unlike the few previous studies [15, 16], none of subjects with HPV in semen showed ASAs.

Likewise, we did not observe associations between sperm parameters and the risk of detecting HPV in semen. As this may have been influenced by the relatively low percentage of patients with HPV-positive semen samples, we cannot rule out whether inflammatory action of HPV infection in the male urogenital tract may exert a potential impact on semen quality.

In patients in whom genotyping was successful, we observed the presence of strains considered to be at high risk for the development of cervical cancer in 13/15 subjects (86.7%), indicating the need for a careful gynecological monitoring of women with HPV-positive partner.

The genotypes identified in our study are analogous to those found in most of the previous literature [7‐9, 32, 36, 38, 45, 47] but different from those discovered by other authors [10‐13, 33, 42], suggesting a different prevalence based on the geographic area examined. It is not possible to exclude the variability deriving also from the different molecular investigations used to detect and to genotype the viral genome. Furthermore, it should be stressed that the low concentrations in which HPV could be present in a biological fluid such as semen, may underestimate the study of its prevalence and the assessment of the various strains.

In recent years, attention regarding the potential impact of HPV infection on andrological health has increased and several papers have advanced the hypothesis that HPV may constitute a risk factor for male infertility [10, 11, 13, 38] and could impact on both natural and assisted reproductive outcomes, such as pregnancy rate and miscarriage rate.

Although some authors demonstrated the ability of HPV to bind the head of spermatozoa at the equatorial segment [12, 14, 35, 46, 48, 50], it remains to be investigated the origin of HPV-DNA in seminal fluid and its viral activity. Luttmer et al. reported a firm association between HPV in semen and penile scrapes, suggesting that the presence of the viral genome in semen may be due to contamination of HPV-positive exfoliated keratinocytes from the penile epithelium [46]. To corroborate this hypothesis, the authors performed fluorescence in situ hybridization (FISH) for HPV-DNA and immunocytochemistry for the HPV-L1 and HPV-E4 proteins, proving the presence of viral genome on spermatozoa in agreement with previous studies [12, 14, 48, 50], but no HPV-L1. This observation would demonstrate that HPV positivity in semen could be caused by free viral DNA that is released from exfoliated keratinocytes and that adheres to sperm heads [46].

In line with this advice, a recent study revealed HPV-DNA also in semen of infertile patients affected by azoospermia with an infection rate of 14.3%, suggesting the hypothesis of a contamination from penile or urethral epithelial cells as a possible origin of HPV-DNA found in semen [35].

The detection of seminal HPV in azoospermic men was observed also in a previous study with a prevalence of 40% in this subgroup of patients [38].

In our study, we detected HPV-DNA in seminal plasma of a patient affected by cryptozoospermia (patient #20) and one with azoospermia (patient #175), suggesting that the presence of HPV in semen would not necessarily be linked to the presence of spermatozoa but could result from a contamination due to epithelial desquamation of the genital tract, despite the absence of visible genital lesions.

In support of this hypothesis, we found no potentially infectious traces of HPV in semen as demonstrated by the absence of viral RNA transcripts in positive samples. Our study is one of the few that has investigated HPV expression in human semen. Only Lai et al. detected HPV16 and 18 RNA in seminal fluid suggesting that semen may act as vector for the transmission of HPV [51]. However, further studies will be needed to assess the infectiousness of seminal HPV and its impact on reproductive health.

It should be highlighted that, whatever the origin of HPV, its detection in semen must be an alarm for clinicians because it suggests that in the male genital tract the virus is present and could be carried to uterine cervix of female partner with negative consequences not only for her health but also in both natural and assisted reproduction. To date, the impact of HPV-DNA, although not transcriptionally active, on fertilization and embryonic development is not yet clear but a putative negative effect on reproductive outcomes, especially in ART, cannot be excluded, as suggested by previous literature [17‐20].

In 2011, Foresta et al. demonstrated that HPV16-transfected human spermatozoa were able to penetrate the hamster oocyte and viral genes were actively transcribed by the penetrated oocyte [14]. To date, the possible impact of HPV on embryonic development is not well defined but in vitro experiments proved that HPV-transfected trophoblast cells show an increased rate of apoptosis and a reduced placental invasion into the uterine wall [52‐54]. This evidence could explain the increased risk of miscarriage and a reduced chance of ongoing pregnancy in patients undergoing ART, as reported by a recent meta-analysis that elucidated the effects of seminal HPV presence on reproductive outcomes [55]. In addition, a recent study showed a significant association between the presence of HR-HPV DNA in semen and recurrent pregnancy loss, suggesting an alleged detrimental impact of the seminal HPV presence on reproductive success [43]. Finally, it should be stressed that the possible consequences of HPV on ART treatment outcomes could represent a further burden with a negative impact on emotional, psychological and sexual aspects of the couple undergoing ART programs [56], requiring a dedicated evaluation.